Defining the Clinically Meaningful Outcomes for Arthroscopic Treatment of Femoroacetabular Impingement Syndrome at Minimum 10-Year Follow-up

The Timing of Surgery Is Crucial

Alexander Zimmerer,*†‡ MD, Viktor Janz,‡ MD, Christian Sobau,† MD, Georgi I. Wassilew,‡ MD, and Wolfgang Miehlke,† MD

Investigation performed at the Department of Orthopaedics, University Medicine Greifswald, Greifswald, Germany

Background: Arthroscopic treatment of femoroacetabular impingement syndrome (FAIS) has become a common procedure. However, meaningful long-term clinical outcomes have not been defined.

Purpose: To define the minimal clinically important difference (MCID), substantial clinical benefit (SCB), and patient acceptable symptomatic state (PASS) for the modified Harris Hip Score (mHHS) at a minimum 10-year follow-up in patients undergoing arthroscopic treatment for FAIS and identify preoperative predictors for achievement of the MCID, SCB, and PASS.

Study Design: Case-control study; Level of evidence, 3.

Methods: A consecutive series of patients undergoing arthroscopic treatment for FAIS between 2007 and 2009 with a minimum 10-year follow-up was analyzed. Patient data included patient characteristics, radiographic parameters, and the pre- and post-operative mHHS and visual analog scale (VAS) for pain score. Paired t tests were used to compare the patient-reported outcome measures (PROMs). The MCID was determined by calculating half of the standard deviation, and SCB and PASS were calculated by the anchor method. Correlation and logistic regression analyses were conducted to identify predictors for the achievement of the MCID, SCB, and PASS.

Results: A total of 44 patients (27 men, 17 women) were included. The mean age and body mass index were 42.2 years (range, 16-67 years) and 22.3 kg/m² (range, 16.76-29.78 kg/m²), respectively. The MCID, absolute SCB, net change SCB, and PASS of the mHHS were calculated to be 19.6, 90.1, 31.5, and 84.4 points, respectively. Preoperative symptom duration was identified as an independent predictor for the achievement of meaningful clinical outcomes. The median symptom durations for patients who achieved the MCID, absolute SCB, net change SCB, and PASS were 11.7, 9.1, 9.0, and 10.8 months, respectively. The median symptom duration for patients who did not achieve the MCID, absolute SCB, net change SCB, and PASS were 15.8, 17.4, 17.3, and 18.4 months, respectively. No other statistically significant correlations were found.

Conclusion: The preoperative duration of symptoms was identified as an independent predictor for achievement of the MCID, SCB, and PASS. These findings can be helpful in accelerating the transition to surgical treatment of FAIS.

Keywords: femoroacetabular impingement syndrome; 10-year follow-up; MCID; PASS; SCB
In addition to the MCID, substantial clinical benefit (SCB) is increasingly reported. SCB is defined as the clinical value that the patient thinks to be considerable. The MCID is the lower bound and tracks the minimum improvement goal, whereas SCB gauges the upper bound, the best possible outcome. Thus, the MCID can be determined by calculating half of the standard deviation of the outcome measure, which is attributable to individuals. An ICC of 1 indicates perfect agreement. We found very good agreement between the 2 observers (ICC, 0.98).

### Surgical Technique

All hip arthroscopies were performed by a single fellowship-trained hip surgeon (W.M.) at a high-volume hospital. All hip arthroscopies were performed with the patient in the supine decubitus position and under general anesthesia. The patients were positioned on a traction table with a well-padded perineal post, and the ipsilateral hip was distracted. In total, 2 standard arthroscopy portals were used during the surgery: the anterolateral and midanterior portal. A periperal capsulotomy but no interportal capsulotomy was performed. Labral repair or routine capsular closure was not performed at our institute during the inclusion period of this study. If labral damage was encountered intraoperatively, selective labral debridement was performed sparingly to preserve the suction seal between the labrum and femoral head. The labrum was not routinely repaired, as there was not much evidence available during the eligibility period. Cartilage damage was treated by chondroplasty or microfracturing according to the International Cartilage Repair Society (ICRS) stages. In the case of anterior pincer morphology, the anterior rim was carefully trimmed using a round bur without decreasing the amount of anterior bony coverage. Femoroplasty was performed if cam morphology was present.

### Psychometric Analyses

The modified Harris Hip Score (mHHS) was assessed preoperatively and at the latest follow-up (minimum, 10 years). Patients also reported their visual analog scale (VAS) for pain score at these points. To quantify the clinical significance of meaningful outcome achievement, the MCID, SCB, and PASS were calculated for the mHHS. MCID was determined by calculating half of the standard deviation of the mHHS as described by Norman et al. The absolute and net change SCB values were calculated using an anchor-based method. The net change SCB indicates a change in the outcome measure that is considered substantial, while an absolute SCB indicates an overall outcome score that is substantial. At the latest follow-up, patients were asked the following anchor.

*Address correspondence to Alexander Zimmerer, MD, ARCUS Sportklinik, Rastatterstr. 17–19, Pforzheim, Germany 75179 (email: zimmerer@sportklinik.de).

1ARCUS Sportklinik Pforzheim, Germany.

2Department of Orthopaedics, University Medicine Greifswald, Greifswald, Germany.

3Final revision submitted August 27, 2020; accepted September 21, 2020.

One or more of the authors has declared the following potential conflict of interest or source of funding: W.M. has received personal fees from Arthrex and Richard Wolf. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.

Ethical approval for this study was obtained from the regional ethics committee of Baden-Württemberg, Germany (ref No. F-2019-006).
question: “Since your hip arthroscopy, how would you rate your overall physical ability?” Possible responses were much worse, worse, slightly worse, no change, slightly improved, improved, and much improved. Patients who responded with slightly worse, no change, or slightly improved were designated as the no-change group. The corresponding difference between the no-change group and much-improved group was used to define the SCB. Nineteen patients were assigned to the much-improved group and 17 patients to the no-change group.

PASS was calculated by use of an anchor-based method. Patients were asked the following question at the latest follow-up7,35: “Taking into account all the activities you have during your daily life, your level of pain, and also your functional impairment, do you consider that your current state is satisfactory?” Thirty-two of the patients responded yes and 12 responded no.

The SCB and PASS for the mHHS were calculated using a receiver operating characteristic (ROC) curve analysis3; an area under the curve >0.8 was considered predictive of patients who did or did not achieve SCB and PASS. The cutoff point was defined using the Youden Index.50

To determine whether there are preoperative patient characteristics that may predict achieving the MCID, SCB, and PASS, Spearman correlation analysis and logistic regression analysis were conducted. Variables used in the correlation and regression analyses were age, sex, BMI, smoking status, symptom duration in months before surgery, and radiographic analysis including alpha angle, LCEAm, and Tönnis grade.

Descriptive statistics for all continuous variables were reported as means ± standard deviations. Continuous data were analyzed with independent and paired t tests. The Levene test for variance was performed. Statistical analyses were conducted using SPSS Statistics for Windows (Version 26.0.0; IBM).

RESULTS
Patient Characteristics and Radiographic Measurements
A total of 44 patients met the inclusion criteria and were included in the analysis (Figure 1). There were 61.4% male hips (27/44). The mean age was 42.2 ± 13.3 years (range, 16-67 years), the mean body mass index (BMI) was 22.3 ± 3.01 kg/m² (range, 16.76-29.78 kg/m²), and the mean follow-up was 11.0 ± 0.8 years (range, 10.0-12.0 years) (Table 1). Four of the 44 hips required revision surgery (3 revision arthroscopies and 1 anteverting periacetabular osteotomy). There have been no complications observed in any of the patients.

The majority of hips had preoperative Tönnis grade 1 (32 hips; 72.7%), while the remaining 12 hips (27.3%) had Tönnis grade 0. The mean preoperative alpha angle was 65.6° ± 13.3° (range, 50°-75°), which was significantly reduced to 45.6° ± 4.8° (range, 40°-55°) postoperatively (P < .001). The mean preoperative LCEA was 31.9° ± 4.8° (range, 26°-40°), which was significantly reduced to 28.5° ± 3.5° (range, 26°-35°) postoperatively (P = .001) (Table 2).

Analysis of Pre- Versus Postoperative Reported Outcome Score Measurements
Analysis of preoperative and long-term follow-up reported mHHS values demonstrated statistically significant improvement (55.6 ± 10.4 [range, 11.0-64.4] vs 89.3 ± 10.7 [range, 52.8-100] points; P < .0001). In addition, there was a statistically significant improvement in the VAS score for pain (6.6 ± 1.5 [range, 4-10] vs 2.3 ± 1.3 [range, 0-9] points; P < .0001).

Table 1

| Value                                    |
|------------------------------------------|
| Laterality                               |
| Right                                    |
| 24 (54.5)                                |
| Left                                     |
| 20 (45.5)                                |
| Sex                                      |
| Male                                     |
| 27 (61.4)                                |
| Female                                   |
| 17 (38.6)                                |
| Age, y                                   |
| 42.2 ± 13.3 (range, 16-67)               |
| Body mass index, kg/m²                   |
| 22.3 ± 3.01 (range, 16.76-29.78)         |
| Follow-up, y                             |
| 11.0 ± 0.8 (range, 10.0-12.0)            |
| Procedures performed                     |
| Femoroplasty                             |
| 41 (93.2)                                |
| Acetabuloplasty                          |
| 35 (79.5)                                |
| Labral debridement                       |
| 40 (91)                                  |

aData are presented as n (%) or mean ± SD (range).
Achievement MCID, SCB, and PASS

The MCID for the mHHS at a mean 11 ± 0.8 years (range, 10.0-12.0 years) of follow-up was 19.6. The ROC curve analysis for calculating the SCB and PASS are provided in Figures 2 to 4. The mHHS threshold scores for achieving absolute SCB, net change SCB, and PASS a mean 11 ± 0.8 years (range, 10.0-12.0 years) of follow-up were 90.1, 31.5, and 84.4, respectively. A total of 39 (89%) patients achieved the MCID mHHS, 26 (59%) achieved the absolute and net change SCB mHHS, and 33 (75%) achieved the PASS mHHS, respectively.

Correlation and Logistic Regression Analyses

The correlation analysis showed a moderate linear association between preoperative symptom duration and the MCID ($P = .024$), absolute SCB ($P = .001$), net change SCB

**TABLE 2**

|                  | Preoperative | Postoperative | $P$   |
|------------------|--------------|---------------|-------|
| Alpha angle (Dunn view), deg | 65.6 ± 13.3 (50-75) | 45.6 ± 4.8 (40-55) | $<.001$ |
| LCEA, deg        | 31.9 ± 4.8 (26-40) | 28.5 ± 3.5 (26-35) | $.001$  |
| Tönnis angle, deg| 7.0 ± 4.5 (2-13)   | NA             | NA    |
| Tönnis grade, n (%) | 12 (27.3)    | NA             | NA    |

*Data are shown as mean ± SD (range) unless otherwise indicated. Boldface $P$ values indicate statistically significant between-group differences ($P < .05$). LCEA, lateral center-edge angle; NA, not applicable.*

![ROC-Curve Analysis for absolute SCB mHHS](image1)

**Figure 2.** Histogram of the receiver operating characteristic (ROC) curve analysis of the postoperative score distribution for the absolute SCB modified Harris Hip Score (mHHS) (area, 0.833; SE, 0.068; 95% CI 0.693-0.913; $P = .005$). SCB, substantial clinical benefit.

![ROC-Curve Analysis for net change SCB mHHS](image2)

**Figure 3.** Histogram of the receiver operating characteristic (ROC) curve analysis of the postoperative score distribution for the net change SCB modified Harris Hip Score (mHHS) (area, 0.851; SE, 0.080; 95% CI 0.695-0.999; $P = .001$). SCB, substantial clinical benefit.

![ROC-Curve Analysis for PASS mHHS](image3)

**Figure 4.** Histogram of the receiver operating characteristic (ROC) curve analysis of the postoperative score distribution for the PASS modified Harris Hip Score (mHHS) (area, 0.984; SE, 0.059; 95% CI 0.723-0.929; $P = .005$). PASS, patient acceptable symptomatic state.
Previous studies reported the MCID, SCB, and PASS for patient outcomes after arthroscopic treatment of FAIS. There has been an increased interest in reporting meaningful clinical outcomes. The mean durations of symptoms for patients who achieved the MCID, absolute SCB, net change SCB, and PASS were 11.7 ± 10.8 months (range, 3.0-18.0 months), 9.1 ± 10.7 months (range, 3.0-18.0 months), 10.8 ± 10.8 months (range, 3.0-18.0 months), respectively. The mean durations of symptoms for patients who did not achieve the MCID, absolute SCB, net change SCB, and PASS were 15.8 ± 6.1 months (range, 8.0-51.0 months), 17.4 ± 10.8 months (range, 3.0-51.0 months), 17.3 ± 10.7 months (range, 3.0-51.0 months), and 18.4 ± 6.2 months (range, 7.0-51.0 months), respectively. The mean durations of symptoms differed significantly between both groups for MCID, absolute SCB, net change SCB, and PASS (each \(P < .0001\)). There were no other statistically significant correlations found between preoperative variables and the MCID, absolute SCB, net change SCB, and PASS (\(P > .05\)). The correlation analysis is summarized in Table 3.

Preoperative predictors of achieving a minimal threshold of meaningful clinical outcome based on MCID included a shorter preoperative pain duration (OR, 0.835; 95% CI, 0.779-0.935; \(P = .048\)). None of the other examined variables were found to be independent predictors for achievement of the MCID mHHS. A shorter preoperative pain duration could be identified as a preoperative predictor for achieving a maximum threshold of a meaningful clinical outcome based on absolute SCB (OR, 0.821; 95% CI, 0.720-0.935; \(P = .003\)) and net change SCB (OR, 0.819; 95% CI, 0.717-0.930; \(P = .003\)). None of the other examined variables were found to be independent predictors for achievement of absolute SCB or net change SCB mHHS. Preoperative predictors of achieving a higher threshold of meaningful clinical outcome on PASS included a shorter preoperative pain duration (OR, 0.858; 95% CI, 0.764-0.935; \(P = .009\)). None of the other examined variables were found to be independent predictors for achievement of PASS mHHS (Table 4).

**TABLE 3**

| Variable               | MCID Value | Absolute SCB Value | Net Change SCB Value | PASS Value |
|------------------------|------------|--------------------|----------------------|------------|
| Sex                    | 0.157      | 0.004              | 0.005                | -0.083     |
| Age                    | 0.139      | -0.028             | -0.027               | 0.599      |
| BMI                    | 0.263      | 0.234              | 0.126                | 0.123      |
| Smoking                | 0.106      | 0.492              | -0.182               | 0.236      |
| Duration of symptoms   | 0.342      | 0.024              | 0.001                | 0.001      |
| Alpha angle            | 0.258      | 0.298              | 0.299                | 0.062      |
| LCEA                   | 0.129      | 0.028              | 0.031                | 0.054      |
| Tönnis grade           | 0.154      | 0.305              | 0.176                | 0.280      |

*Boldface P values indicate statistically significant between-group differences (\(P < .05\)).* BMI, body mass index; LCEA, lateral center-edge angle; MCID, minimal clinically important difference; SCB, substantial clinical benefit.

DISCUSSION

There has been an increased interest in reporting meaningful patient outcomes after arthroscopic treatment of FAIS. Previous studies reported the MCID, SCB, and PASS for the mHHS at short- and medium-term follow-ups. However, there are no reports for long-term follow-ups. This study reports the MCID, SCB, and PASS for the mHHS at a minimum 10-year follow-up. The MCID, absolute SCB, and PASS for the mHHS were calculated to be 19.6, 90.1, 31.5, and 84.4 points, respectively. Furthermore, we identified the preoperative duration of symptoms as an independent predictor for achievement of the MCID, SCB, and PASS.

Recent studies showed that patients with a preoperative duration of FAIS-associated symptoms of 2 or more years before hip arthroscopy experience inferior outcomes and a lower frequency of clinically significant outcome improvement than patients with a shorter duration of symptoms at short- or medium-term follow-up. Our study confirms these findings at long-term follow-up. Our results show that patients with a longer preoperative duration of symptoms achieved a significantly less MCID, SCB, and PASS for the mHHS compared with patients with a shorter preoperative duration of symptoms. Furthermore, binary logistic regression analysis identified preoperative symptom duration as an independent predictor for MCID, SCB, and PASS achievement. One reason for this may be a worsening of the pathology due to the longer duration of symptoms. In our study, 75% of the hips could be assigned to Tönnis grade 1. This factor is extremely important and must be integrated into the decision-making process to fulfill patients’ expectations. In addition, these findings should encourage physicians to accelerate the transition to surgical treatment of patients undergoing conservative therapy. Other studies reported obesity, smoking, and age as additional risk factors influencing achievement of the MCID, SCB, and PASS. Our results could not confirm these findings. Nevertheless, the study group did not include any obese patients (BMI, >30 kg/m²) and the correlation analysis almost reached significance, so that an influence of the BMI on the clinical outcome cannot be excluded with certainty.

The MCID for the mHHS has been described at various time points after hip arthroscopy. However, there was a noticeable spread of the described values. Chahal et al first reported an MCID for the mHHS of 20.1 points 1 year postoperatively. This value 1 year postoperatively is noticeably higher than the MCID of 6.9 points recently described by
Nwachukwu et al.\textsuperscript{34} published a 5-year value for the MCID, anchor-based method, Nwachukwu et al.\textsuperscript{34} chose a calculating the MCID.\textsuperscript{9,42} While Chahal et al.\textsuperscript{8} used an valuable improvements after surgery.\textsuperscript{34} In the same study, arthroscopic treatment of FAIS, as most patients report been shown to not being suitable for patients undergoing distribution-based method. The anchor-based method has higher MCID values obtained in our study have a different slightly lower. Since both studies were performed using a distribution-based method to calculate the MCID, the higher MCID values obtained in our study have a different origin. Nwachukwu et al.'s\textsuperscript{34} study presented a mean mHHS value of 78.2 points at the 5-year follow-up, compared with our mean mHHS value of 89.3 points at the 10-year follow-up. However, the preoperative values were comparable (57.5 and 55.6 points, respectively). The cause of this difference in MCID could be that the proportion of men was higher in our study (61.4\% compared with 36.7\%). However, this cannot be determined conclusively. One difference, though, which is evident for the study collectives, is the BMI, which is 4 points higher in the study by Nwachukwu et al.\textsuperscript{34} compared with our collective (26 versus 22 kg/m\textsuperscript{2}). However, Nwachukwu et al.\textsuperscript{34} stated only the mean value with standard deviation, so no adequate conclusions can be drawn about the number of obese patients in their study.

Another outcome parameter that has been reported in recent times is the SCB. The absolute values reported in the literature for the mHHS at 1- and 5-year follow-ups are between 82.5 and 94.4 points.\textsuperscript{34,36} The SCB of our cohort at the 10-year follow-up is therefore consistent with the values described above. The same applies to the PASS of our cohort, which was determined to be 84.4 points and therefore constant with the values reported in the literature: 84.1 points for the 1-year follow-up and 83.6 points for the 5-year follow-up.\textsuperscript{7,34}

### Limitations

There are some limitations to this study. The small cohort size must be mentioned. On the one hand, this is because hip arthroscopy was in the establishment phase during the investigated time period. On the other hand, though, the indications were more generously defined at that time, so that patients who underwent hip arthroscopy are unlikely to receive arthroscopic treatment today.\textsuperscript{11} There is also a high degree of selection within the cohort. Merely hips with no or minimal signs of osteoarthritis (Tönnis grade <2) were included. Similarly, the study population did not include obese patients, so the influence of BMI may be underrepresented, and therefore, a possible influence of BMI or degree of osteoarthrosis could not be adequately assessed. In addition, patients who received subsequent THA were excluded, as the mHHS was not viable for this group. This fact may have led to a missed identification of potential risk factors for failure. A further limitation is the use of the mHHS, for which a high-ceiling effect has been demonstrated. In recent years, other PROMs have been established that seem to be more suitable for younger patients and do not show this ceiling effect.\textsuperscript{15,29,44} However, these PROMs had not yet been established, so that existing scores, such as the mHHS, were recorded at that time. Furthermore, the labrum and capsule were not routinely repaired, as there was not much evidence available during the eligibility period. Nowadays the labrum is considered to be preserved because of its biomechanical properties.\textsuperscript{18,47} However, Menge et al.\textsuperscript{31} demonstrated that hip arthroscopy for FAIS with labral debridement or repair resulted in significant improvements in the PROMs and satisfaction of patients who did not eventually require THA at long-term follow-up.

| Table 4: Binary Logistic Regression Model for MCID, SCB, and PASS\textsuperscript{a} |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Variable        | OR              | Lower Bound     | Upper Bound     | P Value         |
| MCID            |                 |                 |                 |                 |
| Sex             | 0.958           | 0.895           | 1.089           | .115            |
| Age             | 0.947           | 0.859           | 1.046           | .277            |
| BMI             | 0.923           | 0.903           | 1.025           | .456            |
| Smoking         | 0.590           | 0.493           | 0.632           | .683            |
| Duration of symptoms | 0.835     | 0.779           | 1.001           | .048            |
| Alpha angle     | 0.896           | 0.789           | 0.986           | .123            |
| LCEA            | 1.023           | 0.986           | 1.062           | .789            |
| Tönnis grade    | 0.436           | 0.390           | 0.515           | .633            |
| Absolute SCB    |                 |                 |                 |                 |
| Sex             | 0.667           | 0.598           | 0.735           | .579            |
| Age             | 1.001           | 0.948           | 1.052           | .989            |
| BMI             | 0.843           | 0.813           | 0.967           | .356            |
| Smoking         | 0.923           | 0.785           | 1.235           | .360            |
| Duration of symptoms | 0.821     | 0.720           | 0.935           | \textbf{.003}  |
| Alpha angle     | 0.971           | 0.917           | 1.027           | .301            |
| LCEA            | 1.130           | 1.001           | 1.277           | .079            |
| Tönnis grade    | 0.693           | 0.612           | 0.735           | .832            |
| Net change SCB  |                 |                 |                 |                 |
| Sex             | 0.664           | 0.596           | 0.733           | .578            |
| Age             | 1.002           | 0.947           | 1.053           | .987            |
| BMI             | 0.845           | 0.811           | 0.964           | .359            |
| Smoking         | 0.921           | 0.783           | 1.232           | .365            |
| Duration of symptoms | 0.819     | 0.717           | 0.930           | \textbf{.003}  |
| Alpha angle     | 0.974           | 0.921           | 1.026           | .301            |
| LCEA            | 1.133           | 1.004           | 1.279           | .083            |
| Tönnis grade    | 0.695           | 0.618           | 0.736           | .845            |
| PASS            |                 |                 |                 |                 |
| Sex             | 0.767           | 0.698           | 0.825           | .596            |
| Age             | 0.940           | 0.875           | 1.015           | .114            |
| BMI             | 0.863           | 0.823           | 0.987           | .389            |
| Smoking         | 0.953           | 0.915           | 1.135           | .378            |
| Duration of symptoms | 0.858     | 0.764           | 0.935           | \textbf{.009}  |
| Alpha angle     | 0.981           | 0.927           | 1.017           | .341            |
| LCEA            | 1.105           | 0.998           | 1.178           | .109            |
| Tönnis grade    | 0.815           | 0.789           | 0.912           | .897            |

\textsuperscript{a}Boldface P values indicate statistically significant between-group differences (P < .05). BMI, body mass index; LCEA, lateral center-edge angle; MCID, minimal clinically important difference; PASS, patient acceptable symptomatic state; SCB, substantial clinical benefit.
CONCLUSION

This study reports the MCID, SCB, and PASS for the mHHS for the long-term outcomes of patients undergoing arthroscopic treatment of FAIS. Therefore, we identified the pre-operative duration of symptoms as an independent predictor for achievement of the MCID, SCB, and PASS. Patients with a pre-operative duration of symptoms longer than 12 months experienced a lower frequency of clinically significant outcome improvements. These findings can be helpful in accelerating the transition to surgical treatment of FAIS.

ACKNOWLEDGMENT

The authors thank Dr Marcus Vollmer (Institute of Bioinformatics, Greifswald, Germany) for his support regarding statistical analysis. We acknowledge support for the Article Processing Charge from the DFG (German Research Foundation, 393148499) and the Open Access Publication Fund of the University of Greifswald.

REFERENCES

1. Basques BA, Waterman BR, Ukwuani G, et al. Preoperative symptom duration is associated with outcomes after hip arthroscopy. Am J Sports Med. 2018;47(1):131-137.
2. Beck M, Kalhor M, Leunig M, Ganz R. Hip morphology influences the pattern of damage to the acetabular cartilage. J Bone Joint Surg Br. 2005;87-B(7):1012-1018.
3. Berliner JL, Brodie DJ, Chan V, SooHoo NF, Bozik KJ. Can preoperative patient-reported outcome measures be used to predict meaningful improvement in function after TKA? Clin Orthop Relat Res. 2017;475(1):149-157.
4. Bozik KJ, Chan V, Valone FH, Feeley BT, Vail TP. Trends in hip arthroscopy utilization in the United States. J Arthroplasty. 2013;28(8):140-143.
5. Byrd JWT. Hip arthroscopy: patient assessment and indications. Instr Course Lect. 2003;52:711-719.
6. Cancienne J, Kunze KN, Beck EC, Chahla J, Suppauksom S, Nho SJ. Influence of cigarette smoking at the time of surgery on postoperative outcomes in patients with femoroacetabular impingement: a matched-pair cohort analysis. Am J Sports Med. 2019;47(5):1138-1144.
7. Chahal J, van Thiel GS, Mather RC, et al. The patient acceptable symptomatic state for the modified Harris Hip Score and Hip Outcome Score among patients undergoing surgical treatment for femoroacetabular impingement. Am J Sports Med. 2015;43(8):1844-1849.
8. Chahal J, van Thiel GS, Mather RC, Lee S, Salata MJ, Nho SJ. The minimal clinical important difference (MCID) and patient acceptable symptomatic state (PASS) for the modified Harris Hip Score and Hip Outcome Score among patients undergoing surgical treatment for femoroacetabular impingement. Orthop J Sports Med. 2014;2(7 Suppl 2):2325967145S0010.
9. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56(6):395-407.
10. Cvetanovich GL, Weber AE, Kuhns BD, et al. Clinically meaningful improvements after hip arthroscopy for femoroacetabular impingement in adolescent and young adult patients regardless of gender. J Pediatr Orthop. 2018;38(9):465-470.
11. Domb BG, Chen SL, Shapira J, Maldonado DR, Lall AC, Rosinsky PJ. The evolution of hip arthroscopy: what has changed since 2008—a single surgeon’s experience. Arthroscopy. 2020;36(3):761-772.
12. Editorial commentary: PASSing the test versus acing it: understanding clinically significant outcome improvement in arthroscopic hip surgery. Arthroscopy. 2019;35(5):1463-1465.
13. Flores SE, Sheridan JR, Borak KR, Zhang AL. When do patients improve after hip arthroscopy for femoroacetabular impingement? A prospective cohort analysis. Am J Sports Med. 2018;46(13):3111-3118.
14. Ganz R, Parvizi J, Beck M, Leunig M, Nötzli H, Siebenrock KA. Femoroacetabular impingement: a cause for osteoarthritis of the hip. Clin Orthop Relat Res. 2003;417:112-120.
15. Garbuz DS, Xu M, Sayre EC. Patients’ outcome after total hip arthroplasty. J Arthroplasty. 2006;21(7):998-1004.
16. Glassman SD, Copay AG, Berven SH, Polly DW, Subach BR, Carreon LY. Defining substantial clinical benefit following lumbar spine arthrodesis. J Bone Joint Surg Am. 2008;90(9):1839-1847.
17. Griffin DR, Dickenson EJ, O’Donnell J, et al. The Warwick Agreement on femoroacetabular impingement syndrome (FAI syndrome): an international consensus statement. Br J Sports Med. 2016;50(19):1169-1176.
18. Harris JD. Hip labral repair: options and outcomes. Curr Rev Musculoskelet Med. 2016;9(4):361-367.
19. Harris JD, Brand JC, Cote MP, Faugac CT, Dhawan A. Research pearls: the significance of statistics and perils of pooling. Part 1: Clinical versus statistical significance. Arthroscopy. 2017;33(6):1102-1112.
20. Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am. 1969;51(4):737-755.
21. Katz NP, Paillard FC, Ekman E. Determining the clinical importance of treatment benefits for interventions for painful orthopedic conditions. J Orthop Surg Res. 2015;10(1):24.
22. Kemp JL, Collins NJ, Makiadi S, Schache AG, Machotka Z, Crossley K. Hip arthroscopy for intra-articular pathology: a systematic review of outcomes with and without femoral osteoplasty. Br J Sports Med. 2012;46(9):632-643.
23. Kuhlman GS, Domb BG. Hip impingement: identifying and treating a common cause of hip pain. Am Fam Physician. 2009;80(12):1429-1434.
24. Kunze KN, Nwachukwu BU, Beck EC, et al. Preoperative duration of symptoms is associated with outcomes 5 years after hip arthroscopy for femoroacetabular impingement syndrome. Arthroscopy. 2020;36(4):1022-1029.
25. Kvien TK, Heiberg T, Hagen KB. Minimal clinically important difference (MCID/MCID) and patient acceptable symptom state (PASS): what do these concepts mean? Ann Rheum Dis. 2007;66(Suppl 3):iii40-iii41.
26. Litrenta J, Mu BH, Ortiz-Declet V, et al. Hip arthroscopy successfully treats femoroacetabular impingement in adolescent athletes. J Pediatr Orthop. 2020;40(3):e156-e160.
27. Locks R, Utsunomiya H, Briggs KK, McNamara S, Chahla J, Philippson MJ. Return to play after hip arthroscopic surgery for femoroacetabular impingement in professional soccer players. Am J Sports Med. 2017;46(2):273-279.
28. Martin RL, Kiyan BR, Christoforetti JJ, et al. Minimal clinically important difference and substantial clinical benefit values for the 12-item International Hip Outcome Tool. Arthroscopy. 2019;35(2):411-416.
29. Marx RG, Jones EC, Atwan NC, Closkey RF, Salvati EA, Sculco TP. Measuring improvement following total hip and knee arthroplasty using patient-based measures of outcome. J Bone Joint Surg Am. 2005;87(9):1999-2005.
30. McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1(1):30-46.
31. Menge TJ, Briggs KK, Dornan GJ, McNamara SC, Philippson MJ. Survivorship and outcomes 10 years following hip arthroscopy for femoroacetabular impingement. J Bone Joint Surg Am. 2017;99(12):997-1004.
32. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582-592.

33. Nötzli HP, Wyss TF, Stoecklin CH, Schmid MR, Treiber K, Hodler J. The contour of the femoral head-neck junction as a predictor for the risk of anterior impingement. J Bone Joint Surg Br. 2002;84(4):556-560.

34. Nwachukwu BU, Beck EC, Kunze KN, Chahla J, Rasio J, Nho SJ. Defining the clinically meaningful outcomes for arthroscopic treatment of femoroacetabular impingement syndrome at minimum 5-year follow-up. Am J Sports Med. 2020;48(4):901-907.

35. Nwachukwu BU, Chang B, Beck EC, et al. How should we define clinically significant outcome improvement on the iHOT-12? HSS J. 2019;15(2):103-108.

36. Nwachukwu BU, Chang B, Fields K, et al. Defining the “substantial clinical benefit” after arthroscopic treatment of femoroacetabular impingement. Am J Sports Med. 2017;45(6):1297-1303.

37. Nwachukwu BU, Rebolledo BJ, McCormick F, Rosas S, Harris JD, Kelly BT. Arthroscopic versus open treatment of femoroacetabular impingement. Am J Sports Med. 2016;44(4):1062-1068.

38. Ortiz-Declet V, Yuen LC, Schwarzman GR, Chen AW, Perets I, Domb BG. Return to play in amateur soccer players undergoing hip arthroscopy: short- to mid-term follow-up. Arthroscopy. 2020;36(2):442-449.

39. Perets I, Craig MJ, Mu BH, Maldonado DR, Litrenta JM, Domb BG. Midterm outcomes and return to sports among athletes undergoing hip arthroscopy. Am J Sports Med. 2018;46(7):1661-1667.

40. Perets I, Rybalko D, Chaharbakhshi EO, Mu BH, Chen AW, Domb BG. Minimum five-year outcomes of hip arthroscopy for the treatment of femoroacetabular impingement and labral tears in patients with obesity. J Bone Joint Surg Am. 2018;100(11):965-973.

41. Pietrzak JRT, Donaldson MJ, Kayani B, Rowan FE, Haddad FS. Hip arthroscopy: a narrative review of the current literature. J Musculoskelet Disord Treat. 2018;4(3):057.

42. Sedaghat AR. Understanding the minimal clinically important difference (MCID) of patient-reported outcome measures. Otolaryngol Head Neck Surg. 2019;161(4):551-560.

43. Shaw C. Femoroacetabular impingement syndrome: a cause of hip pain in adolescents and young adults. Mo Med. 2017;114(4):299-302.

44. Thorborg K, Tijssen M, Habets B, et al. Patient-reported outcome (PRO) questionnaires for young to middle-aged adults with hip and groin disability: a systematic review of the clinimetric evidence. Br J Sports Med. 2015;49(12):812.

45. Tönnis D. Normal values of the hip joint for the evaluation of x-rays in children and adults. Clin Orthop Relat Res. 1976;119:39-47.

46. Werner BC, Chang B, Nguyen JT, Dines DM, Gulotta LV. What change in American Shoulder and Elbow Surgeons score represents a clinically important change after shoulder arthroplasty? Clin Orthop Relat Res. 2016;474(12):2672-2681.

47. Westermann RW, Day MA, Duchman KR, Glass NA, Lynch TS, Rosneck JT. Trends in hip arthroscopic labral repair: an American Board of Orthopaedic Surgery Database Study. Arthroscopy. 2019;35(5):1413-1419.

48. Wiberg G. The anatomy and roentgenographic appearance of a normal hip joint. Acta Chir Scand. 1939;83(Suppl 58):7-38.

49. Wolfson TS, Ryan MK, Begly JP, Youm T. Outcome trends after hip arthroscopy for femoroacetabular impingement: when do patients improve? Arthroscopy. 2019;35(12):3261-3270.

50. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-35.